(OTC Pink: IMUN), announced today that equity partner, Cytocom, Inc., has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study CYTO-201 for the treatment of COVID-19.
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”